Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Total Liabilities for 4 consecutive years, with $697.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 10.35% to $697.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $697.3 million, a 10.35% increase, with the full-year FY2025 number at $697.3 million, up 10.35% from a year prior.
  • Total Liabilities was $697.3 million for Q4 2025 at Phathom Pharmaceuticals, up from $662.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $697.3 million in Q4 2025 to a low of $111.0 million in Q1 2022.
  • A 4-year average of $433.5 million and a median of $495.8 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 125.37% in 2024, then increased 10.35% in 2025.
  • Phathom Pharmaceuticals' Total Liabilities stood at $239.6 million in 2022, then surged by 103.07% to $486.6 million in 2023, then rose by 29.86% to $631.9 million in 2024, then rose by 10.35% to $697.3 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Total Liabilities are $697.3 million (Q4 2025), $662.8 million (Q3 2025), and $656.1 million (Q2 2025).